InMed Pharmaceuticals (INM) announces it has been granted an international Patent Cooperation Treaty, PCT, patent in the first of several jurisdictions where the patent has been filed. Titled “Cannabinoid analogs and methods for their preparation”, this patent protects the use of several proprietary small molecule compounds and methods of their preparation, including the drug candidates screened for InMed’s Alzheimer’s disease and dry age-related macular degeneration programs. This Patent No. 417531 has been issued in Mexico and holds a 20-year term.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INM:
- InMed announces ‘positive’ results from in vivo preclinical Alzheimer’s study
- InMed’s INM-901 Shows Promising Results in Preclinical Alzheimer’s Study
- Mahindra & Mahindra Transfers Equity Shares to Employee Stock Option Grantees
- InMed Pharmaceuticals files to sell 3M common shares for holders
- InMed Pharmaceuticals’ 2024 AGM Results Announced